{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:17:56Z","timestamp":1761005876234,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","strokejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Stroke and Cerebrovascular Diseases"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.jstrokecerebrovasdis.2016.12.035","type":"journal-article","created":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T23:48:34Z","timestamp":1486165714000},"page":"1171-1181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Evaluation of the Efficacy and Safety of Direct Oral Anticoagulants in Japanese Patients\u2014Analysis of Pharmaceuticals and Medical Devices Agency Data"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0703-4997","authenticated-orcid":false,"given":"Yasuo","family":"Terayama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.035_bib0010","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.035_bib0015","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"ROCKET AF investigators: rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.035_bib0020","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.035_bib0025","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"ENGAGE AF-TIMI 48 investigators: edoxaban vs. warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.035_bib0030","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1185\/03007995.2014.907140","article-title":"Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients","volume":"30","author":"Laliberte","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.035_bib0035","first-page":"1486","article-title":"New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation","volume":"70","author":"Chatterjee","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.035_bib0040","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s40264-014-0235-y","article-title":"A cross-country comparison of rivaroxaban, spontaneous adverse event reports and concomitant medicine use with the potential to increase the risk of harm","volume":"37","author":"McDonald","year":"2014","journal-title":"Drug Saf"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.035_bib0045","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/pds.3648","article-title":"An international comparison of spontaneous adverse event reports and potentially inappropriate medicine use associated with dabigatran","volume":"24","author":"McDonald","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.035_bib0050","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1253\/circj.CJ-14-1209","article-title":"Intracranial hemorrhage caused by non-vitamin K antagonist oral anticoagulants (NOACs)","volume":"79","author":"Saji","year":"2015","journal-title":"Circ J"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.035_bib0055","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2147\/VHRM.S68117","article-title":"A clinician's perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation\u2014full speed ahead or proceed with caution?","volume":"10","author":"Yang","year":"2014","journal-title":"Vasc Health Risk Manag"},{"author":"PMDA: Pharmaceuticals and Medical Devices Agency","key":"10.1016\/j.jstrokecerebrovasdis.2016.12.035_bib0060"},{"year":"2015","series-title":"Medical ranking 2015","key":"10.1016\/j.jstrokecerebrovasdis.2016.12.035_bib0065"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.035_bib0070","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/2042098615618171","article-title":"Spontaneously reported haemorrhagic adverse events associated with rivaroxaban and dabigatran in Australia","volume":"7","author":"Chen","year":"2016","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.035_bib0075","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/j.jacc.2013.03.020","article-title":"Efficacy and safety of dabigatran etexilate and warfarin in \u201cReal-World\u201d patients with atrial fibrillation. A prospective nationwide cohort study","volume":"61","author":"Larsen","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.035_bib0080","doi-asserted-by":"crossref","DOI":"10.1161\/STROKEAHA.115.011476","article-title":"Cardiovascular, bleeding, and mortality risk of dabigatran in Asians with nonvalvular atrial fibrillation","volume":"47","author":"Chan","year":"2016","journal-title":"Stroke"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.035_bib0085","first-page":"3961","article-title":"Efficacy and safety of dabigatran in a \u201creal-life\u201d population at high thromboembolic and hemorrhagic risk: data from MonaldiCare registry","volume":"19","author":"Russo","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.035_bib0090","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jjcc.2013.05.016","article-title":"\u201cBlue letter effects\u201d: changes in physicians' attitudes toward dabigatran after a safety advisory in a specialized hospital for cardiovascular care in Japan","volume":"62","author":"Suzuki","year":"2013","journal-title":"J Cardiol"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.035_bib0095","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1161\/STROKEAHA.113.004506","volume":"45","author":"Hankey","year":"2014","journal-title":"Stroke"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.035_bib0100","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/35025229","article-title":"Thrombin signaling and protease-activated receptors","volume":"407","author":"Coughlin","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.035_bib0105","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jns.2015.07.031","article-title":"Impact of dabigatran on platelet function and fibrinolysis","volume":"357","author":"Tsantes","year":"2015","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.035_bib0110","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1055\/s-0033-1357490","article-title":"Hemostasis and alterations of the central nervous system","volume":"39","author":"Del Zoppo","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.035_bib0115","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1538-7933.2004.00649.x","article-title":"Synthetic selective inhibitors of coagulation factor Xa strongly inhibit thrombin generation without affecting initial thrombin forming time necessary for platelet activation in haemostasis","volume":"2","author":"Ieko","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.035_bib0120","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1160\/TH07-03-0183","article-title":"In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate","volume":"98","author":"Wienen","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.035_bib0125","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1160\/TH10-02-0097","article-title":"Apixavan, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, Xia, and thrombin","volume":"104","author":"Wong","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.035_bib0130","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/archinternmed.2011.1666","article-title":"Dabigatran association with higher risk of acute coronary events: meta-analysis of non-inferiority randomized controlled trials","volume":"172","author":"Uchino","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.035_bib0135","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1056\/NEJMra1011670","article-title":"The hemostatic system as a moderator of atherosclerosis","volume":"364","author":"Borissoff","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.035_bib0140","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1160\/TH07-08-0481","article-title":"Thrombin and protease-activated receptors (PARs) in atherothrombosis","volume":"99","author":"Martorell","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.035_bib0145","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1517\/14728222.2011.553608","article-title":"Blood coagulation factor Xa as an emerging drug target","volume":"15","author":"Borensztajn","year":"2011","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.035_bib0150","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/cvr\/cvt343","article-title":"Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants","volume":"101","author":"Spronk","year":"2014","journal-title":"Cardiovasc Res"}],"container-title":["Journal of Stroke and Cerebrovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1052305717300022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1052305717300022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T06:38:45Z","timestamp":1760942325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1052305717300022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S1052305717300022"],"URL":"https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2016.12.035","relation":{},"ISSN":["1052-3057"],"issn-type":[{"type":"print","value":"1052-3057"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the Efficacy and Safety of Direct Oral Anticoagulants in Japanese Patients\u2014Analysis of Pharmaceuticals and Medical Devices Agency Data","name":"articletitle","label":"Article Title"},{"value":"Journal of Stroke and Cerebrovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2016.12.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 National Stroke Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}